Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Purpose: Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and approximately 25% of patients with melanoma and common epithelial tumors, represents an attractive target for immune-based therapies. The current trial was carried out to evaluate the ability of adoptively transferred autologous T cells transduced with a T-cell receptor (TCR) directed against NY-ESO-1 to mediate tumor regression in patients with metastatic melanoma and synovial cell sarcoma. Patients and Methods: A clinical trial was performed in patients with metastatic melanoma or metastatic synovial cell sarcoma refractory to all standard treatments. Patients with NY-ESO-1–positive tumors were treated with autologous TCR-transduced T cells plus 720,000 iU/kg of interleukin-2 to tolerance after preparative chemotherapy. Objective clinical responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST). Results: Objective clinical responses were observed in four of six patients with synovial cell sarcoma and five of 11 patients with melanoma bearing tumors expressing NY-ESO-1. Two of 11 patients with melanoma demonstrated complete regressions that persisted after 1 year. A partial response lasting 18 months was observed in one patient with synovial cell sarcoma. Conclusion: These observations indicate that TCR-based gene therapies directed against NY-ESO-1 represent a new and effective therapeutic approach for patients with melanoma and synovial cell sarcoma. To our knowledge, this represents the first demonstration of the successful treatment of a nonmelanoma tumor using TCR-transduced T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationJohnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Self-citationDudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Self-citationA Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationA testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y.-T., Scanlan, M. J., Sahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Self-citationCancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554
Cited by
Items 101–130 of 130
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
New cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179
Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Self-citationSchober, K., Müller, T. R., Gökmen, F., Grassmann, S., Effenberger, M., Poltorak, M., Stemberger, C., Schumann, K., Roth, T. L., Marson, A., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0409-0 · Cited by 178
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
The Role of Tumor Microenvironment in Cancer Immunotherapy
Frankel, T., Lanfranca, M. P., & Zou, W. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_4 · Cited by 173
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
Self-citationSynthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
Roybal, K. T., & Lim, W. A. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052302 · Cited by 124
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133152 · Cited by 109
“In sarcomas, ACT with NY-ESO-1 TCR has demonstrated objective clinical responses in four of six patients with synovial cell sarcoma [8].”
BackgroundCharacterizing the role of monocytes in T cell cancer immunotherapy using a 3d microfluidic model
Lee, S. W. L., Adriani, G., Ceccarello, E., Pavesi, A., Tan, A. T., Bertoletti, A., Kamm, R. D., & Wong, S. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00416 · Cited by 109
“also demonstrated the effectiveness of TCR T cells in the treatment of melanoma and synovial sarcoma (7).”
BackgroundTGF‐β–responsive CAR‐T cells promote anti‐tumor immune function
Hou, A. J., Chang, Z. L., Lorenzini, M. H., Zah, E., & Chen, Y. Y. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10097 · Cited by 106
The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2483 · Cited by 102
Adoptive T-cell therapy for cancer: the era of engineered T cells
Bonini, C., & Mondino, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545552 · Cited by 93
Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
Kumaresan, P. R., da Silva, T. A., & Kontoyiannis, D. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01939 · Cited by 85
“In colon cancer studies, TCR-driven ACT was effective in reducing tumor volume (132), but a high incidence of toxicity was reported, especially when high-avidity TCRs were used (133).”
MethodImmunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81
Self-citationFigueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., Konala, V., Aulakh, A., Littlefield, L., Grizzi, F., et al. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1018419 · Cited by 78
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1147-6 · Cited by 75
Casati, A., Varghaei-Nahvi, A., Feldman, S. A., Assenmacher, M., Rosenberg, S. A., Dudley, M. E., & Scheffold, A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1459-x · Cited by 73
Self-citationT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Tsuchiya, N., Yoshikawa, T., Fujinami, N., Saito, K., Mizuno, S., Sawada, Y., Endo, I., & Nakatsura, T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1346764 · Cited by 67
Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application
Wei, R., Dean, D. C., Thanindratarn, P., Hornicek, F. J., Guo, W., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.024 · Cited by 48
Pollack, S. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1419068 · Cited by 47
“patients following cellular therapy targeting NY-ESO-1, demonstrating thatNY-ESO-1 is an excellent target for these tumor types [63,64].”
BackgroundAlbershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38
Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
Weide, B., Di Giacomo, A. M., Fonsatti, E., & Zitvogel, L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.016 · Cited by 21
Gibadullin, R., Randall, C. J., Sidney, J., Sette, A., & Gellman, S. H. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00016 · Cited by 19
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Kilian, M., Friedrich, M., Sanghvi, K., Green, E., Pusch, S., Kawauchi, D., Löwer, M., Sonner, J. K., Krämer, C., Zaman, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1881 · Cited by 18
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
“In 2011, Robbins et al. demonstrated for the first time the clinical efficacy of NY-ESO-1-targeting TCR-T cells in treating patients with metastatic melanoma or synovial sarcoma (111) .”
Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s
DeRenzo, C., & Gottschalk, S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_10 · Cited by 12
Metadata
- Authors
- Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., Kammula, U. S., Hughes, M. S., Restifo, N. P., Raffeld, M., Lee, C.-C. R., Levy, C. L., Li, Y. F., El-Gamil, M., Schwarz, S. L., Laurencot, C., & Rosenberg, S. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-01
- Volume
- 29
- Issue
- 7
- Pages
- 917-924
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153712501
- Cited by
- 1,632
- References
- 23
- FWCI
- 55.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.